Baird Capital — 2023 Investments

4 investments dated 2023 · listed companies and verified rows first · show all

Alto Neurosciencealtoneuroscience.com in 𝕏NYSE: ANROSeries C · Nov 2023 · $45M

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.

BiotechDigital HealthMental HealthMountain View, US

Amit Etkin(Founder)inAdam Savitz(Executive Officer)inMichael Hanley(Executive Officer)Nicholas Smith(Chief Financial Officer and Chief Business Officer)inAaron Weaver(Director)Po Yu (Jeff) Chen(Director)

Co-investorsAble Partners Alpha Wave Global Gaingels InVivium Capital K2 HealthVentures Korify Capital +12 more

Forjforj.ai inSeed · Jan 2023 · $15M

Forj provides an online community and learning management platform built specifically for associations and professional networks, helping them engage members, deliver digital education, and track analytics.

EdTechEnterprise SoftwareSaaS

Co-investorsKickstart

Parallaxparallax.vc inSeries B · Jun 2023 · $12M

Parallax is a venture capital firm that invests in early-stage, tech-enabled and scalable startups, with a focus on fintech and founders addressing large markets.

Fintech

Co-investorsParallax Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Freemarket

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.